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Summary
Mesenchymal stromal cells (MSC) have emerged as promising cell therapies
for multiple conditions based on demonstrations of their potent
immunomodulatory and regenerative capacities in models of inflammatory
disease. Understanding the effects of MSC on T cells has dominated the
majority of work carried out in this field to date; recently, however, a
number of studies have shown that the therapeutic effect of MSC requires
the presence of macrophages. It is timely to review the mechanisms and
manner by which MSC modulate macrophage populations in order to
design more effective MSC therapies and clinical studies. A complex cross-
talk exists through which MSC and macrophages communicate, a
communication that is not controlled exclusively by MSC. Here, we
examine the evidence that suggests that MSC not only respond to
inflammatory macrophages and adjust their secretome accordingly, but also
that macrophages respond to encounters with MSC, creating a feedback
loop which contributes to the immune regulation observed following MSC
therapy. Future studies examining the effects of MSC on macrophages
should consider the antagonistic role that macrophages play in this
exchange.
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Introduction
Adult progenitor cells such as mesenchymal stromal cells
(MSC) and multi-potent adult progenitor cells (MAPC)
are heterogeneous populations present in a range of adult
tissues, often derived from bone marrow (BM) or adipose
tissue (AT) for experimental use [1]. While both MSC and
MAPC can protect and repair damaged tissues [2–4], it is
their immunomodulatory action that has garnered most
attention over the past decade, with a large number of
studies demonstrating that MSC can suppress inflamma-
tion and adaptive immunity [5–8]. Understandably, the
focus of MSC research has centred on interactions between
MSC and T cells; however, there is now substantial evi-
dence to suggest that MSC-derived soluble factors also sup-
press activation and maturation of innate immune cells,
while skewing early innate reactions towards an anti-
inflammatory phenotype. Studies of adaptive immune
modulation have shown that MSC suppress proliferation
and activation of proinflammatory T cells preferentially,
while promoting anti-inflammatory regulatory T cells
(Treg) simultaneously [6,9,10]. MAPC and MSC that have
been activated or licensed by inflammatory signals such as
interferon (IFN)-g suppress the proliferation of T helper
type 1 (Th1) cells via production of indoleamine 2,3-dioxy-
genase (IDO) [11], while prostaglandin E2 (PGE2) and pro-
grammed death ligand 1 (PDL-1) are required for the
suppression of Th17 activity [5,9,12–14]. The combination
of these effects, with suppression of the inflammatory
storm, make MSC and similar therapies important candi-
dates for intervention against chronic immune pathologies.
The features of the MSC interaction with innate immune
cells are becoming clear. MSC-derived PGE2, the products
of IDO and tumour necrosis factor-inducible gene 6 (TSG-
6) promote the conversion of monocytes and proinflam-
matory macrophages into anti-inflammatory populations
producing interleukin (IL)-10 [15–20]. Proliferation, IFN-
g production and the cytotoxic action of natural killer
(NK) cells is inhibited during co-culture with MSC, with
IDO, PGE2 and human leucocyte antigen G5 (HLA-G5)
playing important roles [21–25]. MSC also suppress adapt-
ive immunity indirectly through shaping the response
VC 2017 British Society for Immunology, Clinical and Experimental Immunology, 188: 1–11 1
Clinical and Experimental Immunology REVIEW ARTICLE doi:10.1111/cei.12929
patterns of dendritic cells (DC). Initially these MSC–DC
interactions appeared bewildering; however, the mecha-
nisms by which MSC direct DC towards a regulatory phe-
notype through IL-6 secretion and Notch signalling have
been clarified recently and characterized by a number of
teams [8,26–29].
The studies summarized above suggest that MSC action
during cell therapy is complex, and involves more than
shaping adaptive immunity: MSC therapy is not a simple
form of global immune suppression that can be reduced to,
or replaced by, a single soluble factor. A complex interac-
tion occurs whereby MSC seem to be licensed or primed by
an inflammatory milieu and respond by producing anti-
inflammatory soluble factors and surface molecules (Fig.
1), suggesting that the early MSC–innate interaction might
be central to successful design of effective therapies. For
example, IDO, which converts tryptophan to kynurenine,
is not produced by MSC under basal conditions, but is
induced in human MSC by exposure to IFN-g [20]. Simi-
larly, TNF-a induces cyclooxygenase 2 (COX-2) expression
by murine BM-MSC [30], and IL-1b has been shown to
prime human MAPC to generate PGE2 [5]. It is also likely
that an intricate communication exists with cells of the
immune system requiring direct cell–cell contact involving
signals such as Notch-Jagged or PDL-1 for MSC to support
Treg and regulatory DC populations. The implication from
these studies is that suppression of innate immune proc-
esses contributes to the beneficial effects seen when MSC
are deployed therapeutically in conditions where an inflam-
matory/cytokine storm is prominent.
Clinical trials using MSC and MAPC have been justified
and performed targeting a range of ischaemic and inflam-
matory conditions including chronic obstructive pulmo-
nary disease (COPD), graft-versus-host disease (GVHD)
and Crohn’s disease, with varying levels of success (www.
clinicaltrials.gov) [31–33]. While much has been done to
understand MSC biology, it is evident from the clinical trial
data that mechanistic understanding lags behind the phe-
nomenological observations of MSC efficacy. The gap in
our understanding is perhaps most evident with regard to
the cross-talk between MSC and macrophages, although a
number of interesting studies have addressed this issue
recently. Multiple and varied mechanisms are emerging by
which MSC modulate macrophage populations; however,
Fig. 1. Mesenchymal stromal cells (MSC) and macrophages cross-communicate. Macrophages are activated by stimuli to produce
proinflammatory factors. This creates a feedback loop whereby proinflammatory cytokines produced by macrophages stimulate MSC to produce
prostaglandin E2 (PGE2) and interleukin (IL)21RA, among other immune modulators.
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the priority, redundancy and species specificity of these
interactions is still unclear. The remainder of this paper
concentrates on the mechanisms by which MSC promote
anti-inflammatory macrophage populations, with a partic-
ular focus on the ways in which macrophages and MSC
interact.
Characterizing macrophage phenotypes
The measurement of the effect of MSC on the inflamma-
tory signature of isolated macrophage populations has
been an important initial topic for study. Macrophages and
their monocytic precursors are professional phagocytes
responsible for the clearance of pathogens and apoptotic
cells. Macrophages can further acquire specialized roles
based on their anatomical location. For example, the pre-
dominant function of alveolar macrophages is the elimina-
tion of particulates, allergens and microbes from the
alveolar surfaces of the lung, while microglia in the brain
are responsible for tissue remodelling and homeostasis
[34]. These issues of macrophage diversity give rise to
problems of interpretability and questions of how applica-
ble data from macrophage cell lines, or from different tis-
sues, can be broadly interpreted and applied.
Regardless of their anatomical location, macrophages are
categorized typically by immunologists into two popula-
tions: the M1 and M2 subsets. M1 macrophages are consid-
ered to be ‘classically activated’, in that they are activated by
Toll-like receptor (TLR) ligands and IFN-g, whereas M2
macrophages are ‘alternatively activated’ by IL-4 and IL-13
[35]. M1 macrophages are considered to mediate defence
against pathogens and secrete proinflammatory cytokines
and inducible nitric oxide synthase (iNOS), while M2 mac-
rophages are a regulatory-like population associated with
production of IL-10. Tumour-associated macrophages
(TAMs) and myeloid-derived suppressor cells (MDSC)
share many of the immunosuppressive features of M2 mac-
rophages [34].
Differentiating between M1 and M2 macrophages (espe-
cially in vivo) can be challenging, and there is plasticity
between the two states. Signal transducer and activator of
transcription 6 (STAT-6) phosphorylation has been a useful
distinguishing marker, as it is phosphorylated in M2 but
not M1 cells. Conversely, in M1 cells STAT-3 and STAT-1
are phosphorylated, often accompanied by activation of the
IFN-g signalling pathway [34]. The most commonly used
method of M1/M2 identification at population level is the
comparative expression of IL-10 and TNF-a measured by
either mRNA or enzyme-linked immunosorbent assay
(ELISA) [19,36,37]. These technological difficulties in char-
acterizing M1/M2 patterns of macrophage response com-
pound the differences seen between studies on
macrophages from different anatomical locations. Never-
theless, in attempts to overcome these potentially con-
founding issues, some groups have measured the
regulatory capacity of macrophages following cell therapy
through introduction of MSC-influenced macrophages
into different functional assays which have helped to
advance and clarify our understanding [38,39].
An array of studies have demonstrated the capacity for
MSC to modulate inflammatory M1 macrophages and pro-
mote anti-inflammatory M2 macrophages [15,37,40]. The
recent progress made in the field of immunometabolism
has been reflected in the MSC field, with Selleri et al. [39]
reporting the capacity of umbilical cord MSC (UC-MSC)
to promote an M2 phenotype in a lactate-dependent man-
ner. The M2 gene expression signature was confirmed by
expression of typical macrophage and M2 gene transcripts
such as CD14, CD16, CD68 and IL-10. Furthermore, these
MSC influenced monocytes showed a greater capacity to
skew activated T cells towards a Th2 phenotype than
monocytes differentiated in the absence of MSC. While no
role was attributed to IDO or IL-6 in this study, inhibition
of lactate production by MSC resulted in lower expression
of CD14, CD16 and CD163 and higher expression of
CD1a. In the presence of UC-MSC, monocytes undergoing
differentiation into DC show decreased mitochondrial
mass and increased spare respiratory capacity, indicating
that MSC-derived lactate shifts the metabolic programming
of monocytes undergoing differentiation towards the M2
phenotype, rather than DC.
MSC-derived soluble factors promote M2
macrophages
MSC-derived soluble factors can promote the conversion
of monocytes or M1 macrophages into an M2-, IL-10-pro-
ducing population [15,19,20]. The role of PGE2 in this
context has been highlighted most recently by Chiossone
et al. [15], who reported that in the presence of MSC,
monocytes driven to differentiate into macrophages by
macrophage colony-stimulating factor (M-CSF) adopted
an alternative phenotype compared to those differentiated
in the absence of MSC (Fig. 2). Macrophages generated in
the presence of MSC expressed higher levels of CD14,
CD16, MHCII, CD11b, CD209, CD163 and CD206, an
effect that was lost when PGE2 production was inhibited
using a COX-2 inhibitor (Table 1). Interestingly, this popu-
lation of MSC-influenced macrophages were unlike IL-4-
driven M2 cells, as macrophages cultured with MSC during
differentiation produced less IL-10 and more IL-1b and
TGF-b than traditionally activated M2 cells.
A role for TSG-6 from MSC on macrophages has also
been investigated. In a xenogeneic administration model,
Ko et al. [38] reported that human BM-MSC elevated
murine pulmonary cell populations expressing major his-
tocompatibility complex (MHC)-II with a significant
increase in the frequency of B2201 CD11b1 cells compared
to controls. Characterization of this population showed
high expression of IL-10, F4/80 and Ly6C (Table 1).
Cross-talk between macrophages and MSC
VC 2017 British Society for Immunology, Clinical and Experimental Immunology, 188: 1–11 3
Furthermore, the B2201 CD11b1 population had greater
capacity than B220–CD11b1 cells to suppress CD3/CD28-
driven T cell proliferation and could prolong the survival
of corneal allografts in vivo, whereas B220–CD11b1 cells
could not. The promotion of this anti-inflammatory popu-
lation required the production of TSG-6 by MSC in both
in-vitro and in-vivo studies [38] (Fig. 2). Similarly, in a
murine model of dextran sodium sulphate (DSS)-induced
colitis, the therapeutic efficacy of intraperitoneally admin-
istered murine BM-MSC is dependent upon the produc-
tion of TSG-6 [41]. In this model MSC form aggregates
with immune cells in the peritoneal cavity, suggesting a
close interaction. Confocal analysis of these aggregates con-
firmed the presence of macrophages using CD68 as a
marker, while flow cytometry was used to confirm the pres-
ence of F4/80-expressing cells. Furthermore, mRNA analy-
sis of the aggregates showed high expression of arginase II,
CC chemokine ligand 22 (CCL22), haem oxygenase 1
(HO-1) and low expression of TNF-a and IL-12, suggest-
ing that the macrophages adopt an M2 phenotype in these
structures. MSC-derived TSG-6 has also been shown to
regulate microglial cells (Table 1); in this case, murine BM-
Fig. 2. Mesenchymal stromal cells (MSC) alter the activation of macrophages using both active and passive mechanisms. Active mechanisms
include the production of soluble factors such as tumour necrosis factor-inducible gene 6 (TSG-6), produce prostaglandin E2 (PGE2) and lactate
which promote macrophages with an anti-inflammatory profile. MSC can also passively affect the profile of macrophages, by being phagocytosed
by macrophages. Dead or effete MSC suppress tumour necrosis factor (TNF)-a production by monocytes. MSC also produce exosomes loaded
with miRNA which down-regulate Toll-like receptor (TLR) signalling in macrophages, making them permissive to the uptake of MSC-derived
mitochondria. Exosomes up-regulate nuclear factor kappa B (NF-jB) signalling in macrophages, while the uptake of mitochondria increases their
phagocytic capacity.
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MSC suppress TNF-a, IL-1b, iNOS and IL-6 production
by lipopolysaccharide (LPS)-stimulated BV2 microglial
cells in a TSG-6-dependent manner (Fig. 2) [42]. These
data, from different systems and using different measure-
ment approaches, indicate that MSC-derived TSG-6 is a
probable key player in the programming of macrophages in
cell therapies, although additional knock-down approaches
may be needed to show definitively if this is a requirement
or a redundant influence.
M1 macrophages respond to MSC
While soluble factors produced by MSC are considered to
dominate their immunomodulatory effects, some groups
have taken an alternative approach to understanding the
effects of MSC on monocytes and macrophages. Recent
studies have suggested that the MSC/macrophage relation-
ship is collaborative, in that phagocytes also respond to the
presence of MSC which may contribute to their anti-
inflammatory effect. For example, heat-inactivated human
AD-MSC are unable to suppress T cell proliferation or induce
regulatory B cells in vitro; however, they have the capacity to
suppress TNF-a production by LPS-stimulated monocytes,
despite being unable to produce anti-inflammatory media-
tors (Fig. 2) [43]. This work demonstrates that the effects
of MSC on monocytes and macrophages are due not only
to soluble factor-mediated anti-inflammatory activity by
MSC, but that the response of the host cells to MSC may
contribute to their regulatory effect. In support of this
hypothesis, a murine model of house dust mite-induced
asthma was used to demonstrate that murine BM-MSC are
phagocytosed by some lung macrophages. Interestingly,
macrophages characterized as F4/801CD11c1 which phag-
ocytosed MSC expressed higher mRNA levels of TGF-b
and IL-10 and lower mRNA levels of IL-6 than cells that
did not engulf MSC (Fig. 2) [37].
Table 1. Cross-talk between macrophages and MSC in model systems
Disease model/assay system Effect of MSC on macrophages Effect of macrophages on MSC Reference
Monocyte to Macrophage M-CSF
driven differentiation
MSC-derived PGE2 skews polarization of
monocytes towards an M2-like
population
n.a. 15
Co-culture of human MSC and naive
lung cells and administration of
MSC to naive mice
MSC promoted the polarization of lung
macrophages towards an anti-
inflammatory population in a
TSG-6-dependent manner
MSC co-cultured in transwell inserts
with lung cells were shown to have
more than a twofold increase in gene
transcripts for TSG-6, TGF-b, IL-1b
and COX-2; however, this was not a
purified macrophage population
38
Murine BM-MSC were cultured with
LPS-stimulated microglia
MSC suppressed production of TNF-a,
IL-1b, IL-6 and iNOS by microglia in a
TSG-6-dependent fashion
n.a. 42
Murine BM-MSC and macrophages in
an LPS-stimulated co-culture
MSC promoted the production of IL-10
by macrophages in a PGE2-dependent
manner
Macrophage derived TNF-a and iNOS
were required for the production of
PGE2 by MSC
19
Human MAPC cultured with human
monocytes or human monocyte-
conditioned media
n.a. MAPC cultured in the presence of
monocytes or conditioned medium
increased production of PGE2 in an
IL-1b-dependent manner
5
Murine Macrophages were stimulated
with silica or LPS in the presence of
conditioned media from murine
MSC-conditioned media
TNF-a secretion by stimulated macro-
phages was decreased by
MSC-conditioned media in an
IL-1RA-dependent fashion
n.a. 36
Murine macrophages were stimulated
with LPS in the presence of murine
BM-MSC
MSC decreased TNF-a production and
increased IL-10 production by LPS-
stimulated macrophages in an IL-1RA-
dependent manner
n.a. 40
Co-culture of human MSC with mouse
and human macrophages or treat-
ment of mouse macrophages with
human MSC-derived exosomes
MSC secrete miRNA containing exosomes
that down-regulate TLR signalling; these
exosomes also increase transcripts of
cytokines associated with NF-jB signal-
ling such as IL-1b, PGE2, TNF and IL-10
Macrophages engulf mitochondria which
are shuttled to the cell membrane of
MSC during mitophagy. This
improves the bioenergetics of
macrophages
44
MSC 5 mesenchymal stromal cells; M-CSF 5 macrophage colony-stimulating factor; BM-MSC 5 bone marrow MSC;
LPS 5 lipopolysaccharide; MAPC 5 multi-potent adult progenitor cells; PGE2 5 prostaglandin E2; TSG-6 5 tumour necrosis factor-inducible
gene 6; IL 5 interleukin; iNOS 5 inducible nitric oxide synthase; TNF 5 tumour necrosis factor; TGF 5 transforming growth factor; NF-
jb 5 nuclear factor kappa B; COX-2 5 cyclooxygenase 2; n.a. 5 not applicable.
Cross-talk between macrophages and MSC
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Two exciting studies have also indicated that other
mechanisms may have a significant impact upon MSC–
macrophage interaction. Phinney et al. described a process
by which macrophages engulf the mitochondria shuttled to
the cell membrane by MSC undergoing mitophagy (Table
1). During this process, MSC secrete simultaneously
miRNA-containing exosomes which, upon uptake by mac-
rophages, down-regulate TLR signalling, rendering macro-
phages receptive to these MSC-derived mitochondria.
These exosomes also increase transcripts of cytokines asso-
ciated with nuclear factor kappa B (NF-jB) signalling such
as IL-1b, PGE2, TNF and IL-10 when compared with silica-
activated macrophages (Fig. 2). Production of these
cytokines by macrophages following MSC treatment may
therefore be responsible for the stimulation of MSC (Fig.
1) [44]. Jackson et al. have also reported the transfer of
MSC mitochondria to macrophages in the lung; here the
transfer is via tunnelling nanotube-like structures [45].
Notably, both the above studies show that macrophage bio-
energetics and phagocytic capacities are enhanced follow-
ing the uptake of MSC mitochondria, which may be
beneficial in increasing microbial clearance in conditions
such as pneumonia and sepsis.
Cross-talk between MSC and macrophages
The importance of cross-talk between MSC and macro-
phages was highlighted in 2009, when it was shown that
murine BM-MSC reprogramme CD11b1 monocytes/mac-
rophages to produce IL-10 in a murine model of sepsis
(Table 1). In this study, PGE2 secretion by MSC was
required to increase IL-10 production by monocytes/mac-
rophages; however, the generation of PGE2 by MSC in this
case was dependent upon TNF-a and iNOS signalling from
monocytes/macrophages [19]. In the human context it has
been shown that human BM-MAPC require priming by
monocyte-derived IL-1b to produce PGE2 [5] (Table 1).
The importance of IL-1 signalling is supported by the fact
that human BM-MSC require the IL-1 signalling pathway
in order to produce PGE2 and TSG-6 [46]. Interestingly,
MSC require IFN-g stimulation to suppress Th1 cell activa-
tion and proliferation (a negative feedback loop) [7,30],
and so it is very likely that MSC maintain a similar cross-
talk with macrophages via IL-1b. This is supported in a
recent study by Ko et al., where human MSC directed lung
macrophages towards an anti-inflammatory phenotype
(Fig. 2). In this case, MSC co-cultured in a transwell system
with mouse lung cells increased expression of gene tran-
scripts for TSG-6, TGF-b, COX-2 and IL-1b; however, it is
unclear if macrophages alone caused this, as the lung cells
represented a mixed population of cell types (Table 1) [38].
The importance of IL-1 in MSC biology has been known
for some time. In 2007 it was reported that IL-1RA pro-
duced by MSC blocked TNF-a production by activated
macrophages [36] (Table 1). IL-1RA production has been
shown to be up-regulated in murine BM-MSC by simulta-
neous IFN-g and IL-1b stimulation, and is an important
contributor to the effects of MSC on macrophage activa-
tion [40] (Fig. 1). CD11b1 monocytes cultured alone, with
MSC or with IL-1RA knock-out MSC were driven to differ-
entiate into macrophages in the presence of M-CSF, and
then activated with LPS. Macrophages which differentiated
in the presence of wild-type MSC produced lower levels of
TNF-a and higher levels of IL-10 than those cultured in
the presence of IL-1RA knock-down MSC [40] (Table 1).
Similarly, in a model of mitogen-driven liver injury,
murine MSC promoted an M2 population of macrophages
in the lung. This was shown by confocal microscopic analy-
sis of double staining for F4/80 and IL-10, combined with
mRNA and immunohistochemical analyses of iNOS and
Arg1 expression in lung tissue. MSC therapy was associated
with an increase in IL-1RA mRNA expression in the lung:
knock-down of IL-1RA in MSC reduced their ability to
ameliorate liver injury. Furthermore, IL-1RA knock-down
MSC did not exhibit the same capacity as control MSC to
increase IL-10 or Arg1 mRNA expression in the lung, or to
decrease iNOS mRNA levels [47].
Human MSC-, murine MSC- and human MSC-derived
exosomes increase IL-1b transcripts in murine macrophages.
Interestingly, however, only murine MSC increased expres-
sion of IL-1 receptor 1, indicating that the cross-talk between
MSC and macrophages is probably species-restricted [44]
and cautions against over-extrapolation from xenogeneic or
humanized mouse studies. Nevertheless, it has been reported
that human BM-MSC require activation to achieve efficacy
in a murine model of LPS-induced acute respiratory distress
syndrome (ARDS) [48]. In this case, activation of MSC by
incubation with serum from ARDS patients for 16 h prior to
administration is associated with an increase in IL-10 and
IL-1RA production by MSC. Animals treated with activated
human MSC exhibited higher levels of IL-10 and lower levels
of IL-1b in bronchoalveolar lavage (BAL) and plasma than
those treated with non-activated MSC. It is possible that the
improved efficacy of MSC therein could be due to increased
IL1RA expression, leading to polarization of M2 macro-
phages. Taken together, these studies suggest that macro-
phage derived IL-1b may stimulate MSC to secrete IL-1RA
and PGE2, and that this process may contribute to the recip-
rocal cross-talk between these cell populations (Fig. 1).
MSC and macrophages: effects at secondary sites
While recent years have seen progress in clarifying the
manner by which MSC and macrophages interact, the
underlying mechanisms behind the phenomena observed
in inflammatory diseases are less clear. The current candi-
dates for cell therapy (including MSC and MAPC) suppress
inflammation effectively in murine models of inflamma-
tory disease [4,7,13,41,49–52]. Efficacy is linked to migra-
tion of MSC to target organs, suppression of T cell
F. Carty et al.
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proliferation, induction of Treg, cytoprotection of damaged
tissue and suppression of inflammation. A role for PGE2
has been demonstrated in MSC- and MAPC-mediated sup-
pression of pathology in murine models of GVHD [53,54],
while in murine models of colitis TSG-6 production is
required for efficacy of BM-MSC [41]. Similarly, preclinical
studies using MSC in pulmonary disorders have provided
promising results [2,4,26,55–60], with MSC therapy being
associated with expansion of Treg, promotion of anti-
inflammatory macrophages, suppression of Th2- and
Th17-associated cytokines and enhanced microbial clear-
ance by macrophages in ARDS [45,48,61].
In the context of the rat model of type 2 diabetes, for
example, intravenously administered UC-MSC can allevi-
ate insulin resistance, increase the numbers of CD1631 and
Arg-11 cells in the stromovascular fraction of adipose tis-
sue and decrease numbers of CD11c1 cells. Expression of
proinflammatory cytokines was lower in the stromal vascu-
lar fraction (SVF) of MSC-treated mice, while Arg1,
CD206 and CD163 expression was higher, suggesting that
MSC promote the M2 phenotype at this site, despite no
MSC being detected in either adipose tissue or the pan-
creas. Interestingly, this study observed an increase in
Arg11 cells in the liver following MSC therapy, which sug-
gests M2 polarization at other sites [62]. This is supported
by a model of corneal allotransplantation, which showed
that intravenously administered MSC were ineffective
when lung monocytes and macrophages were depleted
[38]. Furthermore, in a murine model of cardiac allotrans-
plantation, intravenously administered rat MAPC induced
Treg in a process that required MDSC [52], while a similar
allograft model has also been used to show that intrave-
nously administered murine AD-MSC stimulated MDSC
to induce Th17, which were consequently converted to Treg
[13]. Thus, the presence of monocytes/macrophages are
required for MSC- and MAPC-mediated suppression of
allograft rejection in these instances. Therefore, polariza-
tion of macrophages at sites of MSC distribution in intra-
venous cell therapy may be required for the systemic
response to MSC.
The capacity for both tissue repair and immunomodula-
tion have led to MSC being seen as a potential cell therapy
for asthma [26,55–58]. In these studies, the therapeutic
efficacy of MSC has been attributed to reduction of airway
inflammation, expansion of Treg in vivo and suppression of
Th2- and Th17-associated cytokines. However, in 2013
Mathias et al. [63] showed that depletion of alveolar mac-
rophages abrogated the therapeutic effects of MSC in a
murine model of ovalbumin (OVA)-induced asthma – a
surprising effect, given that the pathology is in the con-
ducting airways. In this study lung macrophages from
MSC-treated mice showed no increase in mRNA levels of
typical M2 markers such as Arg1, Chi313 or IL-10 com-
pared to untreated mice. Despite this, overall IL-10 protein
levels were higher in the lung homogenates of MSC-treated
mice compared to untreated mice, or MSC-treated mice in
which alveolar macrophages were depleted. Therefore, this
study suggests that MSC treatment increases IL-10 produc-
tion by cell populations other than macrophages in the
asthmatic lung (however, this IL-10 production requires
the presence of alveolar macrophages). Similarly, in a
murine model of Der F-induced asthma, human MSC
improved lung function, inhibited inflammation and
decreased Th2 and Th17 cytokines, as expected. However,
this study also showed that MSC were phagocytosed by
some lung macrophages. The macrophages which phagocy-
tosed MSC expressed higher mRNA levels of TGF-b and
IL-10 and lower mRNA levels of IL-6 than macrophages
that did not phagocytose MSC [37]. While both studies
suggest a role for anti-inflammatory macrophages in the
therapeutic efficacy of MSC for asthma, it would be benefi-
cial to characterize M2 populations more thoroughly and
to study further localization in the lung to gain insight into
the interactions occurring.
In the case of ARDS, it is not only the immunomodula-
tory and regenerative capacities of MSC which are useful,
but also their ability to improve microbial clearance by
macrophages. Anti-microbial effects of MSC in a murine
model of Eschericia coli-induced pneumonia through the
production of anti-microbial peptides was first reported in
2012 [64]. More recently a number of studies not only sup-
port this observation, but also implicate a role for macro-
phages in MSC-mediated bacterial clearance. Both
intravenous and intratracheal administration of human
MSC reduced the severity of E. coli-induced pneumonia
through production of the anti-microbial peptide LL-37
and their ability to enhance the phagocytic capacity of host
monocytes and macrophages [65]. Similarly, enhanced
macrophage phagocytosis in ARDS was due to mitochon-
drial transfer from MSC to macrophages in the same model
[45]. Phase I trials have demonstrated a safety profile for
the use of MSC in ARDS, while two Phase IIa trials are cur-
rently under way to determine the efficacy of MSC in this
condition [66].
Both BM-MSC and AD-MSC administered intrave-
nously and intratracheally have shown efficacy in a murine
model of elastase-induced emphysema [4,59]. However,
while BM-MSC and AD-MSC reduced the number of M1
macrophages in the lung, intratracheally administered
MSC from either tissue source did not [59]. Furthermore,
only BM-MSC had the capacity to increase the number of
M2 macrophages in the lung, as characterized by Arg1
expression in the tissue. Interestingly, intravenously admin-
istered BM-MSC which localize to the lung vasculature
were superior at promoting M2 macrophages compared to
intratracheally administered BM-MSC. Similarly, rat BM-
MSC suppressed numbers of CD681COX-21 macrophages
which were associated with inflammation in lung tissue in
a cigarette smoke-induced model of emphysema. Further-
more, this study demonstrated that BM-MSC increased IL-
Cross-talk between macrophages and MSC
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10 production by CD681 macrophages in BAL [60].
Together these data suggest a complex cross-talk between
macrophages in the alveoli, circulation and with therapeu-
tic MSC.
While these preclinical studies suggest that MSC are a
promising therapy for a range of disorders, clinical trials
are needed urgently to confirm unambiguously the efficacy
of MSC for these conditions. In 2004, the first report of
successful MSC therapy in a paediatric case of steroid-
refractory GVHD highlighted the potential of MSC as an
alternative treatment for inflammatory diseases in humans
[67]. Since then a large number of Phase I trials have
proved the safety profile of MSC and MAPC for GVHD
and other conditions [32,68,69]. Response rates to MSC
generally occur in 50–60% of GVHD patients, but even in
this well-studied condition for MSC therapy it is difficult
to make efficacy comparisons between trials and groups
[31,69,70]. These trials show that there is still much to do
to elucidate the exact mechanisms of action of MSC, and
failure to consider issues of dose, timing, route and viabil-
ity at the preclinical stage risks suboptimally designed clini-
cal studies or studies in which efficacy will not be evident,
despite an effective product.
Discussion
While research during the past decade has improved our
understanding of MSC mechanisms of action, it is clear
that much is left to be uncovered. The majority of studies
to date have shown that MSC mediate their immunomo-
dulation through the production of soluble factors in
response to inflammatory stimuli [5,6,71]. These soluble
factors suppress proliferation and activity of T cells while
promoting Treg, regulatory DC and M2 populations in a
myriad of inflammatory diseases [38,54]. Despite the poor
capacity of MSC to migrate to specific regions of inflam-
mation and injury, it is believed that these trophic factors
promote a tolerant immune state which persists long after
MSC have been cleared from the system [72].
Recently, attention has shifted to the additional mecha-
nisms by which MSC therapy may help promote a tolerant
immune state. These studies have highlighted a second
facet of MSC-mediated immunosuppression mediated by
host immune cells responding to the presence of MSC and
altering their immune profile accordingly. Macrophages
phagocytose MSC and alter their proinflammatory signa-
ture following contact with dead MSC, suggesting that
there is a complex cross-talk between MSC and macro-
phages that is not explained simply by the production of
anti-inflammatory mediators by MSC [37,43]. Under-
standing this cross-talk may help resolve one of the para-
doxes of MSC therapy. MSC delivered therapeutically have
a short half-life following intravenous administration in
animal models, and yet therapy has profound long-term
effects. Intravenously administered MSC accumulate
initially in the lung vasculature [73], despite a short sur-
vival time; MSC in this niche would encounter most of the
circulating monocyte populations rapidly, and these could
potentially interact. Furthermore, other studies and our
own unpublished work have shown that MSC can be
detected in distal organs and at sites of inflammation in the
hours following administration [72]. A hallmark of innate
immune cells is the rapidity of their activation; therefore, it
is feasible for MSC to interact with large numbers of
monocytes, macrophages or other cells of the innate
immune system prior to being cleared. Clearly, new experi-
mental methodologies such as whole animal cryovisualiza-
tion will be needed to link cell distribution and cell–cell
interaction during MSC therapies to resolve the paradox of
poor in-vivo survival with high efficacy [54,74]. Further-
more, it is known that MSC derived exosomes promote
NF-jB signalling and subsequent transcription of proin-
flammatory cytokines by macrophages [44], suggesting
that MSC localized in the lung may also be shedding exo-
somes for action in distant tissues. While the cytokines that
macrophages produce in response to MSC may be respon-
sible for the activation or ‘licensing’ of MSC, these induce
important MSC-derived anti-inflammatory signals that, in
turn, modulate macrophages (Fig. 1). Further studies
investigating the response of innate immune cells to the
presence of MSC in vivo may therefore provide new insight
into the exact events which occur following MSC adminis-
tration, and so may improve future prospects for the effi-
cacy of intravenously administered MSC in clinical trials.
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